logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover

AVIR
Atea Pharmaceuticals, Inc.
4.78
2 x 3.43
2 x 5.70
bid
ask
+
0.13
2.80%
2 @ 04:00 PM
4.78 +0.00 (0.00%)
Ytd33.89%
1y32.78%
4.63
day range
4.78
2.78
52 week range
6.45
Open4.68Prev Close4.65Low4.63High4.78Mkt Cap382.53M
Vol472.56KAvg Vol330.75KEPS-2.11P/EN/AForward P/E-2.12
Beta0.17Short Ratio14.25Inst. Own71.14%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0650-d Avg4.76200-d Avg4.161yr Est7.40

AVIR News

benzinga.com
Atea Pharma Completes Patient Enrollment In C-FORWARD, Phase 3 Clinical Trial Outside North America,

Topline Phase 3 Results from C-FORWARD Expected Around Year-End 2026More Than 880 HCV Treatment-Naïv

Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
globenewswire.com
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvi

Topline Phase 3 Results from C-FORWARD Expected Around Year-End 2026 More Than 880 HCV Treatment-Naï